CY1121856T1 - Αντισωματα εξουδετερωσης jcv - Google Patents

Αντισωματα εξουδετερωσης jcv

Info

Publication number
CY1121856T1
CY1121856T1 CY20191100809T CY191100809T CY1121856T1 CY 1121856 T1 CY1121856 T1 CY 1121856T1 CY 20191100809 T CY20191100809 T CY 20191100809T CY 191100809 T CY191100809 T CY 191100809T CY 1121856 T1 CY1121856 T1 CY 1121856T1
Authority
CY
Cyprus
Prior art keywords
jcv
neutralizing antibodies
antibody
virus
jcv neutralizing
Prior art date
Application number
CY20191100809T
Other languages
English (en)
Inventor
Thomas Cameron
Deping Wang
Joseph Arndt
Mia RUSHE
Justin Caravella
Eric Day
Kenneth Simon
Original Assignee
Biogen Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc. filed Critical Biogen Ma Inc.
Publication of CY1121856T1 publication Critical patent/CY1121856T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Σε μία μορφή η γνωστοποίηση παρέχει αντισώματα εξουδετέρωσης έναντι JCV και μεθόδους για την αγωγή της PML. Σε μερικές υλοποιήσεις, μορφές της εφεύρεσης αφορούν ένα απομονωμένο μονοκλωνικό αντίσωμα εξουδετέρωσης JC ιού έναντι πρωτεΐνης καψιδίου JCV VPI (JCV-VP1). Σε μερικές υλοποιήσεις, το αντίσωμα καταστέλλει τη μολυσματικότητα του ιού JC. Σε μερικές υλοποιήσεις, το αντίσωμα δεσμεύει την θήκη δέσμευσης σιαλικού οξέος της JCV-VP1.
CY20191100809T 2012-03-20 2019-07-30 Αντισωματα εξουδετερωσης jcv CY1121856T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613214P 2012-03-20 2012-03-20
PCT/US2013/031842 WO2013142299A1 (en) 2012-03-20 2013-03-15 Jcv neutralizing antibodies

Publications (1)

Publication Number Publication Date
CY1121856T1 true CY1121856T1 (el) 2020-07-31

Family

ID=49223243

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100809T CY1121856T1 (el) 2012-03-20 2019-07-30 Αντισωματα εξουδετερωσης jcv

Country Status (15)

Country Link
US (1) US9567392B2 (el)
EP (2) EP3575311A1 (el)
CA (1) CA2867902C (el)
CY (1) CY1121856T1 (el)
DK (1) DK2828284T3 (el)
ES (1) ES2731757T3 (el)
HR (1) HRP20190937T1 (el)
HU (1) HUE044838T2 (el)
LT (1) LT2828284T (el)
PL (1) PL2828284T3 (el)
PT (1) PT2828284T (el)
RS (1) RS58910B1 (el)
SI (1) SI2828284T1 (el)
TR (1) TR201909801T4 (el)
WO (1) WO2013142299A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2828284T (pt) 2012-03-20 2019-06-17 Biogen Ma Inc Jcv neutralizando anticorpos
WO2013142300A2 (en) 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
ITTO20120570A1 (it) * 2012-06-27 2013-12-28 Pomona Ricerca Srl Anticorpo monoclonale diretto contro il virus jc
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MA51212A (fr) * 2017-12-01 2020-10-07 Novartis Ag Anticorps neutralisant les polyomavirus
CA3142000A1 (en) * 2019-06-19 2020-12-24 Icahn School Of Medicine At Mount Sinai Monoclonal antibodies against jc virus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
ES2429340T3 (es) 2005-03-10 2013-11-14 Morphotek, Inc. Anticuerpos anti-mesotelina
ES2526079T3 (es) 2005-12-20 2015-01-05 Sbi Biotech Co., Ltd. Anticuerpo anti-ILT7
KR100981202B1 (ko) * 2006-05-31 2010-09-10 한화케미칼 주식회사 Ｖｃａｍ－１ 특이적 단일클론항체
US7910702B2 (en) 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
EP2125024B1 (en) 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
AU2008287195A1 (en) 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
PL2307457T5 (pl) 2008-06-25 2022-12-27 Novartis Ag Stabilne i rozpuszczalne przeciwciała hamujące tnf
EP2394163B1 (en) * 2009-02-05 2020-08-19 Biogen MA Inc. Methods for the detection of jc polyoma virus
WO2010129959A1 (en) 2009-05-08 2010-11-11 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the prevention and treatment of lupus nephritis using anti-dsdna germline antibodies
EP2316481A1 (en) 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection
PT2828284T (pt) 2012-03-20 2019-06-17 Biogen Ma Inc Jcv neutralizando anticorpos
WO2013142300A2 (en) 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies

Also Published As

Publication number Publication date
CA2867902A1 (en) 2013-09-26
LT2828284T (lt) 2019-08-26
US20150050271A1 (en) 2015-02-19
ES2731757T3 (es) 2019-11-18
HUE044838T2 (hu) 2019-11-28
DK2828284T3 (da) 2019-06-11
CA2867902C (en) 2023-09-26
US9567392B2 (en) 2017-02-14
EP2828284B1 (en) 2019-05-08
RS58910B1 (sr) 2019-08-30
HRP20190937T1 (hr) 2019-10-04
PL2828284T3 (pl) 2019-11-29
WO2013142299A1 (en) 2013-09-26
TR201909801T4 (tr) 2019-07-22
SI2828284T1 (sl) 2019-10-30
EP2828284A4 (en) 2015-07-22
EP2828284A1 (en) 2015-01-28
PT2828284T (pt) 2019-06-17
EP3575311A1 (en) 2019-12-04

Similar Documents

Publication Publication Date Title
CY1121856T1 (el) Αντισωματα εξουδετερωσης jcv
CY1124182T1 (el) Αντισωματα anti-tmprss2 και θραυσματα δεσμευσης αντιγονου
EA201990243A1 (ru) Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения
CY1121934T1 (el) Αντισωματα anti-fcrn
CY1123068T1 (el) Εξουδετερωτικα αnτισωματα εναντι gp120 και χρηση αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
PH12016501384A1 (en) Human antibodies to pd-l1
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA201791754A1 (ru) АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
EA201890874A1 (ru) Антитела, которые эффективно нейтрализуют вирус гепатита в, и их применение
WO2016196975A8 (en) Neutralizing antibodies to hiv-1 env and their use
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA201890222A1 (ru) Полиспецифические антигенсвязывающие молекулы и их применения
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
WO2017079479A8 (en) Neutralizing antibodies to hiv-1 gp41 and their use
EA201491686A1 (ru) Мультиспецифические антигенсвязывающие молекулы и их применения
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
EA201400875A1 (ru) Антитела к cd47 и способы их применения
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
EA201390933A1 (ru) Антитела против мезотелина и иммуноконъюгаты
CR20150575A (es) Anticuerpos humanos pac1
WO2013059524A3 (en) Antibodies directed against influenza